About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Immunotherapy in Metastatic Triple Negative Breast Cancer: IMpassion130 and Beyond
By
Peter Schmid
4 Videos
September 23, 2019
1 Comment
Login to view comments.
Click here to Login
Featured Video
22:25
Novartis Oncology
The Importance of Dosing and Patient Adherence in HR+/HER2- mBC
Feat.
N. McAndrew
Featured Video
17:04
Novartis Oncology
Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…
Feat.
G. Hortobagyi
Related Content
AUTOPLAY
ON
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
13:03
Novartis Oncology
CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…
Feat.
D. Slamon
04:28
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …
Feat.
S. Tolaney
24:36
ESMO 2022 Conference Coverage
ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates
Feat.
H. Rugo,
J. O'Shaughnessy
20:42
Total Health
2022 Updates in TNBC
Feat.
I. Schlam
03:24
ecancer
SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…
Feat.
V. Kaklamani
13:32
13th Annual Winter Breast Cancer Symposium
2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs
Feat.
W. Gradishar
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
16:08
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Tailoring Post-Neoadjuvant Therapy in TNB…
Feat.
H. Han
09:32
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "TROPiCS-02 Phase 3 Study Final OS Analysi…
Feat.
S. Tolaney
10:22
ESMO 2022 Conference Coverage
ESMO 2022 Updates on mTNBC
Feat.
L. Carey
07:49
ESMO Breast Cancer 2023 Congress Coverage
ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients…
Feat.
H. Rugo
26:03
Total Health
HR+ mBC: Optimizing Endocrine Therapy
Feat.
J. O'Shaughnessy
19:05
International Congress on Cancer Metastasis
Could We Cure Metastatic Breast Cancer?
Feat.
L. Pusztai
04:09
ecancer
Management of HER2+ mBC Treatment Algorithm
Feat.
S. Swain
14:11
ESMO Breast Cancer 2023 Congress Coverage
ESMO Breast Cancer 2023 Highlights: Key Studies Including IMPassion0…
Feat.
P. Tarantino
09:24
The University of Kansas Cancer Center
Treatment Sequence in mTNBC
Feat.
P. Sharma
12:50
Oncology Data Advisor
Expert Perspectives in the Management of TNBC
Feat.
S. Tolaney
13:17
ASCO 2022 Conference Coverage
ASCO 2022 on EFS by Residual Cancer Burden After Neoadjuvant Pembro …
Feat.
L. Pusztai
29:31
Community Oncology Alliance
Current Advances: Triple Negative & Locally Advanced Breast Canc…
Feat.
E. Hamilton
